Pharmaceuticals

With a seasoned regulatory expert at the helm, Arletta Pharma is betting on its dual-action therapy, Lybrido, to transform the underserved FSIAD market.

Beyond deep discounts, COSRX's Amazon Prime Day offensive reveals a masterclass in digital strategy, leveraging viral products to dominate Europe's beauty market.

A strategic pharma alliance scores a major win in Japan's lucrative neurology market, signaling a new competitive front and hope for thousands of patients.

South Korea's Wellness Innercell targets Indonesia's booming wellness market. Its Surabaya-first strategy reveals a calculated blueprint for navigating Southeast Asia.

A prestigious award for its ASD therapy Speragen puts Korean biotech Astrogen in the spotlight. Now, the firm faces the gauntlet of regulatory approval and market entry.

The biotech firm's revenue plummeted as losses soared. But behind the numbers is a calculated pivot to cancer therapy, fueled by a Nasdaq debut and new cash.

AbbVie's latest dividend increase isn't just good news for investors; it's a window into the pharma giant's strategy for navigating future challenges.

For decades, insomnia treatment meant risky sedatives. Now, a new class of drugs is revolutionizing sleep science, promising safer rest for millions.

Life science labs are eagerly exploring AI, but new data reveals a major roadblock: a fragmented digital landscape that keeps true innovation just out of reach.

A new study of 100M insurance claims reveals a shocking failure: nearly 9 in 10 women in some states get no osteoporosis care after a fracture. Why?

Takeda is deploying Boltz's frontier AI across its labs, betting that AI agents can accelerate medicine by acting as a creative partner for scientists.

For years, CIDP patients faced limited options. Now, a wave of targeted therapies promises to transform treatment, sparking a multi-billion dollar market boom.

The Senate's new Naloxone Awareness Day highlights a critical shift. As fentanyl rages, a life-saving drug is moving from ambulances to school hallways.

Quoin Pharma is making a bold bet, building a full commercial operation in Japan for its rare disease drug years before a potential launch. Is this the new model?

Silo Pharma has navigated a critical headwind, regaining Nasdaq compliance. This move provides vital stability, allowing the firm to focus on its true test.

Scienture Holdings' Arbli™ just gained 12.5M covered lives. It's not about the $219M market, but the overlooked patients who can't swallow pills.

A new drug from Cambrian Bio shows promise in activating a key metabolic switch. This could lead to treatments that burn fat while preserving muscle mass.

A new partnership between Charles River and Lilly TuneLab merges AI with nonclinical testing, aiming to fast-track new medicines and level the field for biotechs.

A new grant from The Michael J. Fox Foundation highlights a radical approach to Parkinson's: targeting astrocytes to restore balance and halt neurodegeneration.

A new firm, Nortiva Bio, is launching with tech from MIT to turn daily pills into monthly doses, starting with a contraceptive backed by the Gates Foundation.